Close Menu

NEW YORK (GenomeWeb) – In an encouraging development for the pancreatic cancer space, researchers have shown that using a broader liquid biopsy approach — including both proteomic and circulating DNA analysis — can significantly increase the number of early cancer cases detected in blood samples.

As researchers have come to recognize that treatable genotypes don't turn up equally often in all cancers, it has also become clear that that circulating tumor DNA is not as prevalent or detectable in all cancer types and stages.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.